Skip to content

Moiz Lakhani

3 papers in the library · 17 citations · publishing 2024-2025

Papers

Sort Most recent Most cited

A Global Population-Based Study on the Association Between Ketamine and Esketamine With Suicidality Using WHO VigiBase.

The Journal of Clinical Psychiatry July 7, 2025 Angela T H Kwan, Moiz Lakhani, Joshua D. Rosenblat et al. 2 citations

Background: Ketamine and esketamine have been reported to rapidly alleviate various parameters of suicidality, with antisuicidal effects that may be independent of their rapid-acting antidepressant effects. However, it remains unclear whether ketamine and/or esketamine are associated with the emergence or worsening of suicidality. Methods: In this global observational pharmacovigilance cohort...

DOI: 10.4088/JCP.24m15534 (opens in new tab) Full text (opens in new tab) Esketamine Drug safety Medication safety Adverse drug events +11

Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis.

Journal of Affective Disorders April 1, 2025 Angela T H Kwan, Moiz Lakhani, Kayla M Teopiz et al. 11 citations

To determine whether there is disproportionate reporting of hepatobiliary disorders in the United States (US) FDA Adverse Event Reporting System (FAERS) for individuals prescribed ketamine or esketamine. We identified Medical Dictionary for Regulatory Activities (MedDRA) terms in the FAERS related to hepatobiliary disorders. Formulations of ketamine and esketamine were evaluated for the...

DOI: 10.1016/j.jad.2025.01.054 (opens in new tab) Full text (opens in new tab) Esketamine Drug-induced liver injury Hepatobiliary disorders Hepatotoxicity +9

Ketamine for the Treatment of Psychiatric Disorders: A Systematic Review and Meta-Analysis.

CNS Spectrums November 20, 2024 Angela T H Kwan, Moiz Lakhani, Gurkaran Singh et al. 4 citations

Inadequate response to first- and second-line pharmacological treatments for psychiatric disorders is commonly observed. Ketamine has demonstrated efficacy in treating adults with treatment-resistant depression (TRD), with additional off-label benefits reported for various psychiatric disorders. Herein, we performed a systematic review and meta-analysis to examine the therapeutic applications...

DOI: 10.1017/S1092852924000580 (opens in new tab) Full text (opens in new tab) Anxiety disorders Eating disorders Schizophrenia Substance/alcohol use disorders +5